Twist Bioscience (NASDAQ:TWST) Trading 15.7% Higher - Here's What Happened

Key Points

• Twist Bioscience's stock price surged 15.7% during trading, reaching a high of $32.57 from a previous close of $28.16, although the trading volume was down 47% compared to its average.
• Analysts have mixed ratings for Twist Bioscience, with a consensus rating of "Moderate Buy" and an average price target of $48.56, despite some downward adjustments in price targets by firms like Evercore ISI and Barclays.
• The company reported better-than-expected quarterly earnings, with an EPS of ($0.47) against estimates of ($0.54), and its revenue was also slightly above expectations at $96.06 million.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) traded up 15.7% during trading on Monday . The stock traded as high as $31.70 and last traded at $32.57. 680,883 shares were traded during trading, a decline of 47% from the average session volume of 1,288,962 shares. The stock had previously closed at $28.16.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Evercore ISI decreased their price objective on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a report on Tuesday, October 7th. Barclays decreased their price target on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a report on Thursday, October 2nd. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $48.56.

Twist Bioscience Price Performance

The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $27.98 and a 200 day moving average price of $32.23. The stock has a market cap of $1.98 billion, a PE ratio of -22.62 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CAO Robert F. Werner sold 2,041 shares of the stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $65,699.79. Following the completion of the sale, the chief accounting officer owned 46,413 shares in the company, valued at approximately $1,494,034.47. This trade represents a 4.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Paula Green sold 9,724 shares of the firm's stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $313,015.56. Following the completion of the transaction, the senior vice president owned 114,678 shares of the company's stock, valued at approximately $3,691,484.82. The trade was a 7.82% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,368 shares of company stock worth $2,036,204. 3.01% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TWST. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Twist Bioscience in the first quarter worth about $396,000. D.A. Davidson & CO. lifted its position in shares of Twist Bioscience by 8.0% in the first quarter. D.A. Davidson & CO. now owns 22,710 shares of the company's stock worth $892,000 after buying an additional 1,682 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Twist Bioscience by 27.3% in the first quarter. Envestnet Asset Management Inc. now owns 70,279 shares of the company's stock worth $2,759,000 after buying an additional 15,085 shares in the last quarter. Finally, Xponance Inc. raised its position in Twist Bioscience by 22.0% during the first quarter. Xponance Inc. now owns 5,953 shares of the company's stock valued at $234,000 after purchasing an additional 1,072 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.